Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,014 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A randomized, double-blind, placebo-controlled, phase 3 study of tivantinib in Japanese patients with MET-high hepatocellular carcinoma.
Kudo M, Morimoto M, Moriguchi M, Izumi N, Takayama T, Yoshiji H, Hino K, Oikawa T, Chiba T, Motomura K, Kato J, Yasuchika K, Ido A, Sato T, Nakashima D, Ueshima K, Ikeda M, Okusaka T, Tamura K, Furuse J. Kudo M, et al. Among authors: oikawa t. Cancer Sci. 2020 Oct;111(10):3759-3769. doi: 10.1111/cas.14582. Epub 2020 Aug 26. Cancer Sci. 2020. PMID: 32716114 Free PMC article. Clinical Trial.
Influence of skeletal muscle volume loss during lenvatinib treatment on prognosis in unresectable hepatocellular carcinoma: a multicenter study in Tohoku, Japan.
Fujita M, Abe K, Kuroda H, Oikawa T, Ninomiya M, Masamune A, Okumoto K, Katsumi T, Sato W, Iijima K, Endo T, Fukuda S, Tanabe N, Numao H, Takikawa Y, Ueno Y, Ohira H. Fujita M, et al. Among authors: oikawa t. Sci Rep. 2022 Apr 20;12(1):6479. doi: 10.1038/s41598-022-10514-3. Sci Rep. 2022. PMID: 35444161 Free PMC article.
Objective Response by mRECIST to Initial Lenvatinib Therapy Is an Independent Factor Contributing to Deep Response in Hepatocellular Carcinoma Treated with Lenvatinib-Transcatheter Arterial Chemoembolization Sequential Therapy.
Kuroda H, Oikawa T, Ninomiya M, Fujita M, Abe K, Okumoto K, Katsumi T, Sato W, Igarashi G, Iino C, Endo T, Tanabe N, Numao H, Fukuda S, Iijima K, Masamune A, Ohira H, Ueno Y, Takikawa Y. Kuroda H, et al. Among authors: oikawa t. Liver Cancer. 2022 Feb 15;11(4):383-396. doi: 10.1159/000522424. eCollection 2022 Jul. Liver Cancer. 2022. PMID: 35978602 Free PMC article.
Occurrence of hepatocellular carcinoma 24 years after successful interferon therapy in a patient with chronic hepatitis C: a case report.
Yoshida Y, Yonezawa M, Okamoto T, Fujiwara Y, Suzuki A, Suzuki Y, Endo K, Kakisaka K, Oikawa T, Kuroda H, Miyasaka A, Takikawa Y. Yoshida Y, et al. Among authors: oikawa t. Clin J Gastroenterol. 2019 Apr;12(2):120-127. doi: 10.1007/s12328-018-0915-8. Epub 2018 Oct 19. Clin J Gastroenterol. 2019. PMID: 30341715 Review.
A new model to estimate duration of survival in patients with hepatocellular carcinoma with BCLC intermediate stage.
Ninomiya M, Tsuruoka M, Inoue J, Hiraoka A, Iwata T, Sano A, Sato K, Onuki M, Sawahashi S, Kuroda H, Oikawa T, Fujita M, Abe K, Katsumi T, Sato W, Igarashi G, Iino C, Endo T, Tanabe N, Numao H, Iijima K, Matsumoto T, Ohira H, Ueno Y, Masamune A. Ninomiya M, et al. Among authors: oikawa t. Sci Rep. 2023 Nov 25;13(1):20739. doi: 10.1038/s41598-023-48068-7. Sci Rep. 2023. PMID: 38007597 Free PMC article.
1,014 results